Investors

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, is to commercially launch its innovative weight management solution SlimBiome® Medical ('SlimBiome®') to the European market on May 7, at Vitafoods Europe 2019.

SlimBiome®, which is a CE marked medical device, offers a healthy, hunger-free weight management solution designed for use by itself, or as part of a calorie-restricted diet, to reduce hunger and help users achieve sustainable weight loss. Independent clinical studies show SlimBiome® reduces hunger, cravings for sweet and savoury foods, and fat intake.

Taking place from May 7 until May 9, Vitafoods Europe 2019 brings together nutraceutical expertise from more than 110 countries. This year's event will be held in Geneva, Switzerland and OptiBiotix will be exhibiting alongside Nutrilinea on stand B20.

This commercial launch follows on from the announcement that SlimBiome® was granted medical device status and a CE mark in November 2018 (RNS: 27 November 2018), followed by the appointment of Nutrilinea S.R.L as a manufacturer (RNS: 29 November 2018) and the signature of distribution agreements for Greece, Cyprus (RNS: 4 December 2018) and Bulgaria (RNS: 9 April 2019) as well as the successful commercial launch to the UK market on April 29 2019 (RNS: 24 April 2019).

Fred Narbel, Managing Director of the Prebiotics division, commented: "We are delighted to present SlimBiome® Medical to the EU market at Vitafoods as it is one of the most significant annual nutraceutical events in Europe. The launch allows us to continue to deliver on our sales strategy of building multiple revenue streams across various sales channels because it will help us accelerate the expansion our distribution and sales network in Europe and beyond and support recent distribution agreements we have established."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.